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Abstract 35 
Background: The aim of this study was to explore the natural history of peanut 36 
allergy in childhood in two birth cohorts from the same geographical region in 37 
the South of England.  38 
 39 
Methods: The FAIR birth cohort was established on the Isle of Wight (UK) 40 
between 2001-2002 (n = 969).  Children were followed up prospectively, skin 41 
prick tested (SPT) to peanut allergens at 1, 2, 3 and 10 years and food challenges 42 
performed.  The Isle of Wight (IOW) Birth cohort was established in 1989 (n = 43 
1456). SPTs were performed at 1, 2, 4 and 10 years. Peanut allergy was based on 44 
positive SPT and a good clinical history. 45 
 46 
Results: In the FAIR cohort, the prevalence of sensitization to peanut was 0.4%, 47 
2.0%, 2.0% and 2.4% at 1,2,3 and 10 years respectively.  At 10 years of age, 48 
12/828 (1.5%) children were diagnosed with peanut allergy. One child (8%) 49 
outgrew her peanut allergy between 3 and 10 years and two children (15%) 50 
presented with new onset peanut allergy.  Over the first ten years of life, 13/934 51 
(1.4%) children were diagnosed with peanut allergy.  In the IOW cohort, 6/1034 52 
(0.58%) were diagnosed with peanut allergy at 10 years. We found no significant 53 
differences between the FAIR and the IOW birth cohort for any of the time points 54 
studied. 55 
 56 
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Conclusion: Peanut allergy appears to be stable over the first ten years of life in 57 
our cohorts. There was no significant difference in peanut sensitization or 58 
clinical peanut allergy between 1989 and 2001. 59 
 60 
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Introduction 68 
Prevalence, incidence and time trends of peanut allergy in older children remain 69 
unclear.  Furthermore, it is not known if the prevalence and/or natural history of 70 
peanut allergy during childhood has changed in the last decade, although 71 
sensitization rates to peanut are reported to be stable (1). A systematic review 72 
reported an overall pooled estimate for all age groups of food-challenge-defined 73 
peanut allergy of 0.2% (0.2–0.3) (2). In the USA a systematic review (3) based 74 
their prevalence figures of 0.6% in 6-10 year olds and 0.2% in 11-17 year olds, 75 
mainly on data by Sicherer et al. (4,5). 76 
 77 
In terms of the natural history of peanut allergy, we know from cohorts recruited 78 
from hospital based clinics, that a small proportion (20%) of children with 79 
peanut allergy outgrow it by adolescence and occasionally a relapse may occur 80 
(6). Less is known however about the natural history of peanut allergy in 81 
unselected, population based birth cohorts (7). Recently, Peters et al. (8) 82 
reported a prevalence rate of 1.47% at 4 years in the HealthNuts study. However 83 
this was not a birth cohort as children were recruited at 1 year. 84 
 85 
We recently reported prevalence of peanut allergy (0.58%) and sensitization 86 
(1.3%) at 10 years of age in a cohort born in 1989 (Isle of Wight (IOW) birth 87 
cohort) (7).  In another cross-sectional study, peanut sensitization rates of 3.7% 88 
was reported on the Isle of Wight at 11 years (9). These children (different from 89 
the two birth cohorts analyzed in this study) were born in 1991/1992 and 90 
assessed at only 11 years of age during a school visit.  We have also reported on 91 
the time trends of peanut allergy using data from three different cohorts on the 92 
Isle of Wight when followed up between the ages of 3-4 years (10), who were 93 
born in 1989 (IOW Birth cohort), 1994–1996 (FAB cohort), and 2001–2002 94 
(FAIR birth cohort). Skin prick test (SPT) positivity to peanut and clinical peanut 95 
allergy in children aged between 3-4 years increased significantly from 1993 to 96 
1998/2000, but with no significant change was seen from 1998/2000 to 97 
2004/2005. We now present prevalence and natural history data of peanut 98 
allergy up to 11 years of age in the FAIR birth cohort, born in 2001-2002. In 99 
order to describe time trends of peanut allergy, we have compared the FAIR 100 
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cohort to the IOW birth cohort (born in 1989-90) at 1, 2, 3-4 and 10 years of age. 101 
 102 
Methods 103 
FAIR birth cohort 104 
A birth cohort born on the Isle of Wight (UK) (n = 969) between 2001-2002 was 105 
followed up prospectively (11).  Children were clinically examined and SPT were 106 
performed to milk, wheat, egg, cod, peanut and sesame (ALK Abello) at 1, 2, 3 107 
and 10 years of age. Children were invited for food challenges when indicated at 108 
three and ten years of age.   The Committee on Toxicity advice (UK)(12), which 109 
recommended the avoidance of peanut until 3 years in high risk families, was 110 
still relevant at the time.  Children were therefore first challenged to peanut at 3 111 
years of age. 112 
 113 
Peanut allergy was defined as a positive food challenge or a positive SPT and a 114 
thorough clinical history, as previously reported (7). At 10 years sensitization 115 
was also measured using specific IgE to whole peanut protein and individual 116 
components (ThermoFisher, Uppsala, Sweden). Lupin sensitization and allergy 117 
was determined at 10 years only, using Stallergens SPT solution. 118 
 119 
The IOW Birth cohort 120 
The IOW birth cohort was born in 1989 (13) . SPTs were performed at 1, 2, 4 and 121 
10 years of age using ALK Abello diagnostic extracts. 1034 children were seen at 122 
10 years of age (7). Peanut allergy was defined as a positive SPT and a thorough 123 
clinical history (14). 124 
 125 
In both cohorts SPT was performed using standardised allergen reagents and 126 
methodology by the same research team (15). Allergic sensitization was defined 127 
by a positive SPT, indicated by a mean wheal diameter of 3 mm or greater than 128 
the negative control (saline).  129 
 130 
Specific IgE tests in the FAIR cohort 131 
All children in the FAIR cohort were invited to undergo a blood test, n=246 132 
consented. Specific IgE tests to peanut were performed using ImmunoCap 133 
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(ThermoFisher). Component resolved diagnostic (CRD) tests using ImmunoCap 134 
(ThermoFisher) were performed in all children with a positive specific IgE test to 135 
peanut; these included: Ara h1, Ara h2, Ara h3, Ara h8 and Ara h9 components. 136 
 137 
Food challenges in the FAIR cohort 138 
Food challenges were performed with 2.5g of peanut protein at 3 years of age 139 
followed by a normal age-appropriate portion, calculated from national 140 
consumption data for young children from the UK National Diet and Nutrition 141 
Survey databases (16). At 10 years of age, the PRACTALL (17) recommendations 142 
were in place, therefore challenge doses were adapted to comply with these (i.e. 143 
3.443g of protein). At younger ages in the FAIR cohort, challenges were 144 
performed as double blind placebo controlled food challenge, however at age 10 145 
parents consented to open food challenges only as their children already had 146 
prior diagnosis of peanut allergy. Food challenges were considered positive 147 
based on an adapted version of the PRACTALL (17) recommendations, which is 148 
used as standard clinical practice at the David Hide Asthma and Allergy Clinic on 149 
the Isle of Wight. 150 
 151 
Statistical methods 152 
All data were double entered by different operators on SPSS versions 20 and 21 153 
and were verified (SPSS Inc, Chicago, USA). Prevalence rates were computed, 154 
together with 95% confidence intervals, using the method of Clopper and 155 
Pearson. Numbers indicating loss of follow-up were clearly stated. Fisher’s exact 156 
tests, Odds Ratio and Mann Whitney tests were used to assess risk factors for the 157 
development of peanut allergy. A logistic regression model was used to assess 158 
factors that could independently determine development of peanut allergy. 159 
 160 
Ethical approval for the FAIR study was obtained from the NRES South Central - 161 
Southampton B Research Ethics Committee (REF 10/H0504/11).  Ethical 162 
approval for the IOW study was obtained from the Isle of Wight Local Research 163 
Ethics Committee (Ref 18/98). All parents consented and children provided 164 
assent. 165 
 166 
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Results 167 
Prevalence and cumulative incidence of peanut allergy in the FAIR birth cohort 168 
969 children were recruited and 900/969 (92.9%), 858/969 (88.5%), 891/969 169 
(91.6%) and 827/969 (85%) were assessed at 1, 2, 3 and 10 years of 170 
age.   Prevalence of sensitization to any of the predefined foods was 1.9%, 3.8%, 171 
4.5% and 2.7% at these ages.  Prevalence of sensitization to peanut at these ages 172 
was 0.4%, 2.0%, 2.0% and 2.4% (Table 1).  173 
 174 
At 3 years of age 11/891 (1.2%; 95% CI: 0. 6 – 2.2%) children were diagnosed 175 
with peanut allergy. At 10 years of age, 12/828 (1.5%; 95% CI:  0. 8 – 2.5%) 176 
children were diagnosed with a peanut allergy. SPT at either 1, 2, 3 or 10 years 177 
was available for 849 children. Over the first ten years of life, 27/849  (3.2%; 178 
95% CI: 2.0% - 4.4%) children were sensitized to peanut. Information on peanut 179 
allergy was available for 934 children at either 1, 2, 3 or 10 years. 13/934 (1.4%; 180 
95% CI: 0.6 - 2.2%) children were diagnosed with a peanut allergy over the first 181 
ten years. 182 
 183 
Looking at peanut specific IgE levels at 10 years, 29 children were sensitized to 184 
peanut using a cut off of 0.35 kUA/l, 31 using 0.2 kUA/l as a cut off point17 and 36 185 
using 0.1 kUA/l17 as a cut off point. All children with a positive SPT to peanut (n = 186 
14) who consented to a blood test (n = 10) showed levels of specific IgE above 187 
0.35 kUA/l.  188 
 189 
Natural history of peanut allergy in the FAIR birth cohort over the first 10 years of 190 
life 191 
Table 2 summarizes all 27 children who were sensitized to peanut at some point 192 
during their first 10 years of life. They showed a variable time course, from early 193 
sensitization to late sensitization, with some cases of sensitization in specific 194 
time points only. Table 3 summarizes the 13 children with clinical peanut allergy 195 
over the first 10 years of life, and their sensitization status measured by SPT, as 196 
well as specific IgE. One child (8%) outgrew peanut allergy between 3 and 10 197 
years of age. Two children (15%) presented with new onset peanut allergy.  The 198 
CRD results of these children showed 5 of the 8 children having levels of Ara h2 > 199 
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0.35 kUA/l. Of the 12 children diagnosed with peanut allergy at age 10 years, five 200 
children had positive Ara h2 levels > 0.35 kUA/L, two children had Ara h2 levels 201 
< 0.35 kUA/l and five children did not have blood tests. 202 
 203 
Time trends in peanut allergy in the FAIR and IOW birth cohorts 204 
Although both sensitization and clinical allergy were clearly higher in the FAIR 205 
cohort, the differences were not statistically significant.  Looking at peanut 206 
allergy in the two cohorts the data shows a prevalence of 0.62% versus 1.2% at 207 
3-4 years and 0.58% vs. 1.5% at 10 -11 years  (Figures 1 and 2).  208 
 209 
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Table 1: Sensitization patterns in the FAIR cohort over the first ten years of life 210 
 211 
 212 
 213 
 214 
  215 
Sensitisation 1 year 
(n=763) 
2 years 
(n=658) 
3 years 
(n=642) 
10 years 
(n=588) 
Specific IgE at 10 years (n=246) 
  n (%) n (%) n (%) n (%) n (%) 
Any of the predefined allergens 20 (2.6) 54 (8.2) 76 (11.8) 145 (24.7) 124 (50.4) 
Any of the predefined food 
allergens (milk, egg, cod, 
wheat, peanut, sesame) 
17 (1.9) 25 (3.8) 29(4.5) 
23 (3.6) 
87 (14.6) 
16 (2.7%) 
fx5 
56 (22.8) 
Any of the predefined aero-
allergens 
8 (1.1) 42 (6.4) 70 (10.9) 99 (16.8%) Aero-allergen 
113 (45.9) 
Peanut 3 (0.4) 13 (2.0) 13 (2.0) 14(2.4) 29/57 (50.9) 
Ara h8: 6/33 (18.2) 
Ara h1:2/33 (6.1) 
Ara h2: 6/33 (18.2) 
Ara h3: 2/33 (6.1) 
Ara h9: 1/33 (3.03) 
Lupin       4 (0.68) 3/57 (5.3) 
10 
 
Table 2: Natural history of sensitization and clinical allergy in 27 children of the FAIR cohort over the first 10 years of life  216 
Participant  Sensitized at 1 
year 
Sensitized at 2 
years 
Sensitized at 3 years Peanut allergic at 3 
years 
Sensitized at 10 
years 
Peanut allergic at 
10 years 
1 No Yes Yes Yes Yes Yes 
2 No NA Yes Yes NA Yes 
3 No Yes Yes Yes Yes Yes 
4 NA Yes Yes Yes NA Yes 
5 NA NA Yes Yes Yes Yes 
6 NA NA Yes Yes Yes Yes 
7 No No No No Yes Yes 
8 No Yes Yes Yes Yes Yes 
9 No No Yes Yes NA Yes 
10 No Yes Yes Yes Yes Yes 
11 No Yes NA Yes No No 
12 No NA No No Yes Yes 
13 Yes Yes Yes Yes Yes Yes 
14 Yes No No No No No 
15 Yes Yes No No No No 
16 NA Yes No No No No 
17 No Yes Yes No No No 
11 
 
18 No Yes No No No No 
19 No Yes No No No No 
20 No NA Yes No NA No 
21 No NA Yes No NA No 
22 No No NA No Yes No 
23 No No No No Yes No 
24 No No No No Yes No 
25 No No No No Yes No 
26 No NA No No Yes No 
27 No Yes No No No No 
 217 
No = negative skin prick test of food challenge. Yes= positive skin prick test or food challenge. NA= not applicable (i.e. declined test) 218 
  219 
12 
 
Table 3: Natural history of peanut allergy in the FAIR cohort over the first 10 years of life 220 
 221 
 Participant SPT wheal 
size (mm) at 
1 year 
SPT wheal 
size (mm) at 
2 years 
SPT 
wheal 
size (mm) 
at 3 years 
Peanut 
allergy 
at 3 
years 
SPT wheal 
size (mm) 
at 10 years 
Peanut allergy 
over the first 
10 years of life 
Specific IgE at 
10 years 
(kUA/L) 
CRD at 10 
years 
1 0 7.75 5.5 Yes 6 Yes (Positive 
OFC) 
Fx5 15.2  
Peanut 13.5  
Ara h8 0.09 
Ara h1 0.05 
Ara h2 13 .0 
Ara h3 0.07 
Ara h9 0.28 
2 1.75 NA 4.25 Yes NA Yes (positive 
SPT plus history 
of reactions) 
NA NA 
3 0 9.25 8.75 Yes 8.5 Yes (positive 
OFC in past and 
SPT > 8 mm) 
Fx5 3.5 
Peanut 0.4  
Ara h8 0.01 
Ara h1 0.02 
Ara h2 0.32 
Ara h3 0.18 
Ara h9 0.04 
4 NA 9.5 7.75 Yes NA Yes (positive 
SPT > 8 mm plus 
history of 
reactions) 
NA NA 
5 NA NA 6 Yes 10.75 Yes (positive 
SPT > 8 mm plus 
history of 
reactions) 
Fx5 264 
Peanut 264.5 
Ara h8 0.07 
Ara h1 13.6 
Ara h2 138 
Ara h3 2.07 
Ara h9 0.11 
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6 NA NA 10.5 Yes 7.5 Yes (positive 
SPT > 8 mm plus 
history of 
reactions) 
NA  
7 0 0 0 No 5  Yes (positive 
SPT and history 
of reactions) 
Fx5 0.9 
Peanut 1.5 
Ara h8 0.01 
Ara h1 0.07 
Ara h2 0.15 
Ara h3 0.01 
Ara h9 0.01 
8 0 0 12 Yes 8.5 Yes (positive 
SPT > 8 mm plus 
history of 
reactions) 
Fx5 69 
Peanut 49.7 
Ara h8 0.00 
Ara h1 11.8 
Ara h2 29.5 
Ara h3 7.79 
Ara h9 0.01 
9 0 0 3.5 Yes NA Yes (Positive 
OFC in past and 
still reacting) 
NA NA 
10 0 4.75 11 13.25 √ Yes (positive 
OFC in past and 
SPT > 8 mm) 
NA NA 
11 1.5 0 0 No 10 Yes (positive 
OFC in past and 
SPT > 8 mm) 
Fx5 1.26 
Spec IgE 2.34 
Ara h8 1.47 
Ara h1 0 
Ara h2 1.01 
Ara h3 0.001 
Ara h9 0.003 
12 4.5 8.75 11 Yes 5.5 Yes (Positive 
OFC) 
Fx5 5.03 
Spec IgE 4.65 
Ara h8 0.01 
Ara h1 0.3 
Ara h2 4.65 
14 
 
Ara h3 0.002 
Ara h9 0.01 
13 0 5.5 NA Yes 0 X Fx5 0.75 
Spec IgE 1.93 
Ara h8 0.03 
Ara h1 0.01 
Ara h2 0.02 
Ara h3 0.17 
Ara h9 0.04 
 222 
√ = positive. NA = Not applicable (i.e. declined blood test). CRD = component resolved diagnostics 223 
  224 
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Table 4: Factors associated with the development of peanut allergy at age ten years of life in the FAIR cohort 225 
 Peanut allergy at age 10 
years (n=12) 
No peanut allergy at age 
10 years (n=935)* 
Odds ratio (95% 
confidence interval) 
Fisher’s exact test 
Sensitization to any 
allergen over 10 years 
(n=186) 
12/12 174/835 Inf p=0.000 
Sensitization to any aero-
allergen over 10 years 
(n=175) 
10/13 165/671 Inf p=0.000 
Senitization to any FA 
over 10 years (n=41)  
12/12 29/934 Inf  p= 0.000 
Ever sensitized to grass 
(n=108) 
8/12 100/835 16.727 (4.603 – 65.852) p=0.001 
Any IgE mediated Food 
Allergy (n=31)  
12/12 19/934 Inf p=0.000 
Egg allergy at one year 
(n=16) 
3/13 13/875 22.436 (4.245 – 106.953) p=0.001 
Ever suffered from 
asthma (n =101)  
5/10 96/503 4.2 (1.041 – 17.278) p=0.029 
Ever suffered from 
eczema (n=258)  
10/12 248/815 11.43 (2.486-52.55) p=0.001 
Ever suffered from 
hayfever (n=233)  
7/12 226/815 3.649 (1.146-11.614) p=0.045 
Family history of allergy 
(n=790) 
9/13 781/806 Inf p=0.241 
Any breast feeding  
(n= 598) 
7/12 591/855 0.540 (0.142- 2.061) p=0.000 
* n=947 children have been seen at some point over the 10 years. Inf = infinite 226 
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Factors associated with the development of peanut allergy 227 
In the FAIR cohort, the following factors were associated with the development 228 
of peanut allergy at age 10 years (Table 4):  sensitization over the first ten years 229 
of life to any allergen, any aero-allergen, any food allergen and grass; ever 230 
suffered from asthma, eczema or hayfever, any breastfeeding, as well as egg 231 
allergy at one year. A family history of allergy was not however not associated 232 
with the development of peanut allergy. 233 
 234 
Logistic regression was performed to assess the impact of a number of factors on 235 
the likelihood of developing peanut allergy. The model, containing four variables 236 
(breastfeeding, family history, egg allergy and sensitization to any food allergen) 237 
was statistically significant, predicting 98.9% of participants’ peanut allergic 238 
status correctly, α2 (6, N = 854) = 75.94, p < 0.01. The model as a whole explained 239 
between 8.5% (Cox and Snell R squared) and 66.1% (Nagelkerke R squared) of 240 
the variation. Although this model was very specific, correctly predicting 99.9% 241 
of non-peanut allergic participants; it had low sensitivity, correctly predicting 242 
only 27% of those with peanut allergy. None of the variables made a unique 243 
statistically significant contribution to the model. Sensitization to any food 244 
allergen made the strongest contribution, explaining 20.8% of the variation.  245 
 246 
Discussion 247 
We have shown that in the FAIR cohort at 10 years of age, 2.4% of children were 248 
sensitized to peanut and 1.5% clinically allergic. Between the ages of 3 and 10 249 
years, one child outgrew peanut allergy and two children had new onset peanut 250 
allergy, leading to a cumulative incidence of peanut allergy over the first ten 251 
years of life of 3.0%. Comparing peanut sensitization and peanut allergy in two 252 
cohorts of children born 12 years apart, we found no significant difference in the 253 
prevalence of peanut sensitization at 1, 2, 3-4 and 10 years of age or peanut 254 
allergy at 3-4 or 10 years of age. A number of factors played a role in the 255 
development of peanut allergy, such as egg allergy and eczema in early life. 256 
Family history of allergy and breastfeeding did not independently affect the risk 257 
although they were both contributing factors in a multivariate logistic regression 258 
model.  259 
17 
 
 260 
We found a sensitization rate to peanuts at 10 years of 1.8% in the IOW birth 261 
cohort and 2.4% in the FAIR cohort. We have also described the prevalence of 262 
peanut sensitization in a different IOW school cohort (9) to be 3.7%, which may 263 
indicate either higher rates in that particular cohort or some selection bias as 264 
only 47.4% of the total cohort was recruited. Very few studies have looked at 265 
peanut sensitization in children of this age.  Mustayev et al.( 18) described the 266 
prevalence of sensitization to peanut at 11 years of age in Turkish children as 267 
0.7%.  Asarnoj et al. (19) report a higher rate of peanut sensitization of 7.4% at 268 
age eight years in a Swedish birth cohort, whilst McGowan et al (1) reported a 269 
higher rate again of 10.5% in a cross sectional US population of 6-19 year old 270 
children and adolescents. 271 
 272 
Gupta et al.(20) described the prevalence of self-reported doctor’s diagnosed 273 
peanut allergy in 11- 13 year olds from the US to be 2.3%.  Using similar 274 
methodology in children 11-17 years of age, Sicherer et al. (4,5) reported 275 
prevalences of 0.2%  and 1.7%. In our cohort, 1.4% of children reported a 276 
problem with consuming peanut, but not necessarily based on a doctor’s 277 
diagnosis. Only one previous study has reported peanut allergy in a prospective 278 
cohort study based on oral food challenges, SPTs, and specific IgE measurements 279 
(21). The HealthNuts study recruited 12 month old infants in Australia, born 280 
between 2006-2009 (n = 5276). Of the 156 participants diagnosed with peanut 281 
allergy at age 12 months (2.95% of cohort), 78% had persisting allergy at age 4 282 
years. This is therefore a higher initial diagnosis rate and resolution rate than 283 
observed in either the FAIR or IOW cohorts. In the HealthNuts study, Ara h2, tree 284 
nut, and house dust mite sensitization, coexisting food allergies, eczema and 285 
asthma were not predictive of persistent peanut allergy at age 4 years. In the 286 
FAIR cohort, we reported that sensitization over the first ten years of life to any 287 
allergen, ever having asthma, eczema, hayfever or egg allergy at one year were 288 
associated with the development of peanut allergy by 10 years. Overall the 289 
differences between studies are difficult to disentangle given the different 290 
sampling time periods, ages at recruitment and factors reported. Future 291 
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publications from the HealthNuts study reporting data at age ten years will 292 
enable more direct comparisons to be made.  293 
 294 
In terms of development of peanut allergy, our data confirm that egg allergy and 295 
eczema are significant risk factors for peanut allergy, as reported previously by 296 
Lack et al. (22), the recent LEAP study (23) and the HealthNuts study (21). 297 
Nicolau et al. (24) reported that asthma, eczema, and food allergies were more 298 
common among subjects with peanut allergy, whereas hayfever was more 299 
common in peanut-tolerant children. With respect to diet during pregnancy and 300 
infancy as risk factors for development of peanut allergy, our group has 301 
previously demonstrated that government advice to atopic mothers to avoid 302 
peanut during pregnancy was misunderstood and did not lead to a reduction in 303 
peanut allergy prevalence (25). It remains to be seen whether changes to 304 
national UK infant feeding guidelines will be made following the publication of 305 
the LEAP (23) and Enquiring About Tolerance (EAT) studies (26). 306 
 307 
Comparing SPT or specific IgE testing, we found SPT was a better indicator of 308 
peanut allergy: 29 children had a positive specific IgE to peanut, 14 had a 309 
positive SPT, with 12 found to be peanut allergic at age 10. For specific IgE, a cut 310 
off of > 0.35 kUA/l performed better than 0.1 kUA/l. This is despite the fact that a 311 
0.35 kUA/l cut off point reported by ThermoFisher was due to the initial analytic 312 
ability of the test, and does not have a clinical basis. This cut off was reduced to 313 
0.1 kUA/l as lower detection levels are now possible, but these are not clinical 314 
diagnostic levels(27).  315 
Children with a clinical peanut allergy were sensitised to a range of peanut 316 
components. The majority was sensitised to Ara h2 as all eight children showed a 317 
level of sensitisation to Ara h2; (n=7 above 0.1 kUA/l; n=5 above 0.35 kUA/l). 318 
This is similar to data reported by Nicolau et al.(24) who reported that Ara h2 319 
was the most important predictor of peanut allergy. However, it may not be true 320 
in all populations as Restani et al. (28) identified Ara h3 as the major allergen in 321 
a group of peanut allergic children.  322 
 323 
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A limitation of our study was that the IOW birth cohort were not challenged to 324 
peanut, rather the diagnosis was based on a thorough clinical history and 325 
positive SPT. Although all the children in the FAIR cohort at the age of 10 years 326 
were offered a food challenge, only two consented, both of which were open 327 
challenges. Additionally, less than 25% consented to a blood test, which may 328 
affect the accuracy of the results. Another limitation is that the sample size was 329 
not sufficient to detect statistically significant differences between the two 330 
cohorts. Based on our data, we would require a sample size of 4207 children in 331 
each group at 3 years and 1908 children per group at 10 years of age to detect a 332 
difference with 80% power. Theoretically, if we use these sample sizes and 333 
impute our % of peanut allergy we will find a highly significant increase in 334 
peanut allergy, both at 3 years (p=0.006) and at 10 years (p = 0.004). 335 
 336 
Conclusion 337 
Peanut allergy appears to be stable at 1.5% over the first 10 years of life, with 338 
only about 10% of children outgrowing their peanut allergy and approximately 339 
20% developing new onset peanut allergy. In the 12 years between 1989-2011, 340 
an increase in both peanut sensitization and clinical peanut allergy was noted 341 
but this did not reach statistical significance possibly due to sample size 342 
constraints.  We acknowledge that in some areas of the world, some food 343 
allergies seem to be on the increase (29). It is therefore probably safe to assume 344 
that with sufficient numbers our peanut allergy prevalence may be significantly 345 
increasing, but it is difficult to say for certain as there is such limited data on the 346 
time-trends in food allergy. 347 
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